GSK: Brussels conditionally approves Blenrep
(CercleFinance.com) - GlaxoSmithKline (GSK) announced on Wednesday evening that the European Commission has granted a conditional marketing authorisation for its Blenrep (belantamab mafodotin) as monotherapy for the treatment of multiple myeloma in adults.
It concerns patients who have already received at least four therapies and whose disease is refractory to at least one proteasome inhibitor, an immuno-modular agent and an anti-CD38 monoclonal antibody, and whose disease progressed during the latest therapy.
This decision is based on data from the DREAMM-2 pivotal study, which includes 13-month follow-up data. GSK points out that nearly 50,000 new cases of multiple myeloma are diagnosed each year in Europe.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
It concerns patients who have already received at least four therapies and whose disease is refractory to at least one proteasome inhibitor, an immuno-modular agent and an anti-CD38 monoclonal antibody, and whose disease progressed during the latest therapy.
This decision is based on data from the DREAMM-2 pivotal study, which includes 13-month follow-up data. GSK points out that nearly 50,000 new cases of multiple myeloma are diagnosed each year in Europe.
Copyright (c) 2020 CercleFinance.com. All rights reserved.